Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02236195 · ClinicalTrials.gov registry record · Phase 2
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
A Phase 2 study, sponsored by Mirati Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT02236195 is a Phase 2 study that has completed, run by Mirati Therapeutics. The registered enrollment target is 17 participants.
The verdict
NCT02236195, a Phase 2 study, has completed, sponsored by Mirati Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
Mocetinostat is an orally administered histone deacetylase (HDAC) inhibitor. This study is a Phase 2 trial evaluating the efficacy of mocetinostat in patients that have advanced urothelial carcinoma that has specific changes in tumor genes. Patients must have previously received treatment with chemotherapy that included a "platinum-containing agent" such as cisplatin. The study will enroll in stages, with 15 patients in the first stage. More patients will be added to the study if enough patients having beneficial responses are observed. Mocetinostat will be administered using oral capsules three times each week (eg, Monday, Wednesday and Friday). The study is designed to evaluate whether the number of patients responding to treatment is substantially higher than would be expected with other available treatments.
Interventions
- DRUG Mocetinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02236195
The ClinicalTrials.gov registry entry for NCT02236195 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mocetinostat is the first listed.
NCT02236195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02236195 about?
NCT02236195 is a clinical study titled "Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes". Mocetinostat is an orally administered histone deacetylase (HDAC) inhibitor. This study is a Phase 2 trial evaluating the efficacy of mocetinostat in patients that have advanced urothelial carcinoma that has specific changes in tumor genes. Patients must have previously received treatment with chemo...
What is the current status of trial NCT02236195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2014-10. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02236195?
The interventions under investigation include: Mocetinostat (DRUG).
Who is sponsoring clinical trial NCT02236195?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.